Last updated: February 24, 2026
What is NDC 00536-1411?
NDC 00536-1411 corresponds to Humira (adalimumab), a biologic medication used to treat autoimmune conditions including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. As a leading biologic, it accounts for significant sales in the pharmaceutical market.
Market Overview
Humira held a dominant position among biologics, generating approximately $21.3 billion revenue in 2022 globally (IQVIA, 2023). It faced patent expirations beginning in 2023, opening opportunities for biosimilar competition.
Competitive Landscape
| Product Type |
Brand Name |
Launch Year |
Market Share (2022) |
Key Competitors |
| Original biologic |
Humira |
2002 |
60% (worldwide) |
Other TNF inhibitors (Enbrel, Remicade) |
| Biosimilar |
Amjevita (Amgen), Hadlima (Medius) |
2023 |
Expected 20-25% (2024 projections) |
Upcoming biosimilars from Samsung, Coherus |
| Next-gen biologic |
Skyrizi, Stelara |
2019-2020 |
Increasing share |
Biologic alternatives |
Patent and Regulatory Status
Humira's key patents expired in the US culminating in 2023, with biosimilars entering the market. In the EU, patent expiry plans began around 2018, with biosimilars approved since 2019. The US introduced biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) in 2010, with first approvals happening gradually after 2015.
Price Trends
Historical Pricing
| Year |
Average Wholesale Price (AWP) per 40 mg syringe |
Notes |
| 2012 |
Approximately $3,000 |
Peak prices before biosimilar threat |
| 2020 |
About $2,600 |
Slight decline due to market pressures |
| 2022 |
$2,350 |
Biosimilar entry impacts |
Biosimilar Price Projections
Biosimilars are priced approximately 15-30% below the reference product, leading to significant savings:
| Year |
Estimated Price (per syringe) |
Comments |
| 2023 |
$1,600 - $2,250 |
Biosimilars launched, market competition intensifies |
| 2024 |
$1,400 - $2,000 |
Further price erosion expected as market stabilizes |
Market Share and Revenue Projections
| Scenario |
2023 |
2024 |
2025 |
| Optimistic (rapid biosimilar adoption) |
40% market share |
55% |
65% |
| Conservative (slower adoption) |
20% |
35% |
45% |
Assuming a 50% reduction in average revenue per unit due to biosimilar competition, revenue could decline from approximately $21 billion (pre-patent expiry) to roughly $10-12 billion by 2025.
Key Factors Influencing Pricing and Market Dynamics
- Patent litigation: Patent challenges delay biosimilar market entry in certain regions.
- Pricing negotiations: Payers and government agencies exert pressure to lower prices.
- Market penetration strategies: Biosimilar manufacturers focus on pricing strategies and provider incentives.
- Regulatory policies: Biologic substitution laws vary across states and countries, impacting biosimilar uptake.
- Safety and efficacy perceptions: Healthcare providers' acceptance influences biosimilar adoption rates.
Regional Outlook
| Region |
Expected Biosimilar Adoption |
Price Impact |
Notable Regulations |
| US |
Moderate to high, increasing after 2023 |
20-30% decline |
Substitution laws vary by state |
| EU |
High, with rapid uptake |
25-30% decline |
Universal reimbursement policies |
| Asia |
Variable, growing market |
15-25% decline |
Emerging biosimilar policies |
Market Opportunities and Risks
Opportunities
- Development of next-generation biologics with differentiated mechanisms.
- Expansion into emerging markets with high unmet needs.
- Cost-effective biosimilars with lower production costs.
Risks
- Slower biosimilar adoption impacting revenue decline.
- Manufacturing and supply chain challenges.
- Regulatory hurdles delaying product launches.
Price Projection Summary
| Year |
Estimated Average Price (per syringe) |
Approximate Revenue Impact |
Key Assumptions |
| 2023 |
$1,600 - $2,250 |
50% revenue decline |
Biosimilar entry, patent expirations |
| 2024 |
$1,400 - $2,000 |
Further decline |
Increasing biosimilar market share |
| 2025 |
$1,200 - $1,800 |
Continued decline |
Market stabilization |
Key Takeaways
- Humira's revenue faces erosion as biosimilars gain market share post-patent expiration.
- Price declines are expected to be between 20-30% in core markets within two years.
- The US remains a critical battleground, with variable biosimilar adoption depending on state laws.
- Companies that innovate next-generation biologics or expand into underserved regions can mitigate revenue declines.
- Price projections depend heavily on biosimilar acceptance, regulatory policies, and stakeholder incentives.
FAQs
1. When did patent expiry occur for Humira in the US?
Patent expiry in the US began in 2023, enabling biosimilar market entry.
2. How much will biosimilar prices undercut the original Humira?
Biosimilars are expected to be priced 15-30% lower than the originator, with a typical price around $1,600–$2,250 per syringe.
3. What are the primary factors affecting biosimilar adoption?
Regulatory policies, payer incentives, provider acceptance, and substitution laws influence biosimilar uptake.
4. How will revenue from Humira change by 2025?
Revenue could decline by approximately 50% compared to peak levels, projecting into the $10-12 billion range.
5. Which regions will see the fastest biosimilar adoption?
The European Union and East Asia are expected to lead in biosimilar acceptance, with the US trailing due to regulatory and legal complexities.
References
- IQVIA. (2023). Global Trends in Biologics.
- U.S. Food and Drug Administration (FDA). (2010). Biologics Price Competition and Innovation Act (BPCIA).
- European Medicines Agency (EMA). (2019). Biosimilar Medicines: What You Need to Know.
